REFERENCES

• FrankR.HargreavesR.Clinical biomarkers in drug discovery and development.Nat Rev Drug Discov.2003256658012838269
   PubMed Web of Science ®Google Scholar
• MöllerHJ.JägerM.RiedelM.ObermeierM.StraussA.BottlenderR.The Munich 15-year follow-up study (MUFSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Assessing courses, types and time stability of diagnostic classification.Eur Psychiatry.2010196460466
   Google Scholar
• LeskoLJ.AtkinsonAJ Jr.Use of biomarkers and surrogate endpoints in drug development and regulatory decisionmaking: criteria, validation, strategies.Annu Rev Pharmacol Toxicol.20014134736611264461
   PubMed Web of Science ®Google Scholar
• SpilkerB.Guide to Clinical Thais. Philadelphia, PA: Lippincott-Raven Publishers;1996
   Google Scholar
• BieckPR.PotterWZ.Biomarkers in psychotropic drug development: integration of data across multiple domains.Annu Rev Pharmacol Toxicol.20054522724615822176
   PubMed Web of Science ®Google Scholar
• SchwarzE.BahnS.The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders.Br J Pharmacol.2008153(suppl 1)S133S13618193070
   PubMed Web of Science ®Google Scholar
• LeiserSC.DunlopJ.BowlbyMR.DevilbissDM.Aligning strategies for using EEG as a surrogate biomarker: aA review of preclinical andclinical research.Biochem Pharmacol.2011811408142120937262
   PubMed Web of Science ®Google Scholar
• SteigerA.KimuraM.Wake and sleep EEG provide biomarkers in depression.J Psychiatr Res.20104424225219762038
   PubMed Web of Science ®Google Scholar
• SeierFE.KellnerM.YassouridisA.HeeseR.StrianF.WiedemannK.Autonomic reactivity and hormonal secretion in lactate-induced panik attacks.Am J Physiol.1997272H2630H6389227540
   PubMedGoogle Scholar
• HinkelmannK.YassouridisA.MassR.et al.CCK-4: pPsychophysiological conditioning elicits features of spontaneous panic attacks.J Psychiatr Res.2010441148115320451215
   PubMed Web of Science ®Google Scholar
• HahnT.MarquandAF.EhlisAC.DreslerT.et al.integrating neurobiological markers of depression.Arch Gen Psychiatry.20106836136821135315
   PubMed Web of Science ®Google Scholar
• WongDF.GründerG.BrasicJR.Brain imaging research: does the science serve clinical practice?Int Rev Psychiatry.20071954155817896234
   PubMed Web of Science ®Google Scholar
• KellnerM.KnaudtK.JahnH.HolsboerF.WiedemannK.Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine andpathophysiological consequences.J Psychiatr Res.19983237489693999
   PubMed Web of Science ®Google Scholar
• KellnerM.MuhtzC.DemiralayC.et al.The selective serotonin reuptake inhibitor excitalopram modulates the panic response tocholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.J Psychiatr Res.20094364264818930474
   PubMed Web of Science ®Google Scholar
• HarmerCJ.CowenPJ.GoodwinGM.Efficacy markers in depression.J Psychopharmacol. In press.
   Google Scholar
• CaspiA.SugdenK.MoffittTE.et al.Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.Science.200330138638912869766
   PubMed Web of Science ®Google Scholar
• RischN.HerrelR.LehnerT.LiangKY.et al.Interaction between the serotonin transporter gene 5-HTTLPR), stressful life events, and riskof depression: a meta-analysis.JAMA.20093012462247119531786
   PubMed Web of Science ®Google Scholar
• FergussonDM.NorwoodLJ.MillerAL.KennedyMA.Life stress, 5HTTLPR and mental disorder: findings from a 30-year longitudinal study.Br J Psychiatry.201119812913521282783
   PubMed Web of Science ®Google Scholar
• IsingM.LucaeS.BinderEB.BetteckenT.et al.A genomewide association study points to multiple loci that predict antidepressant drugtreatment outcome in depression.Arch Gen Psychiatry.20096696697519736353
   PubMed Web of Science ®Google Scholar
• LajeG.PerlisRH.RushAJ.McMahonFJ.Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Psychiatr Serv.2009601446145719880459
   PubMed Web of Science ®Google Scholar
• HorstmannS.LucaeS.MenkeA.et al.Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.Neuropsychopharmacology.20103572774019924111
   PubMed Web of Science ®Google Scholar
• McMahonFJ.BuervenichS.CharneyD.et al.Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.Am J Hum Genet.20067880481416642436
   PubMed Web of Science ®Google Scholar
• DomschkeK.LawfordB.LajeG.et al.Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response.IntJ Neuropsychopharmacol.2010139310119236730
   PubMed Web of Science ®Google Scholar
• JacobC.DomschkeK.GajewskaA.WarringsB.DeckertJ.Genetics of panic disorder: focus on association studies and therapeutic perspectives.Expert Rev Neurother.2010101273128420662753
   PubMed Web of Science ®Google Scholar
• BinnemanB.FeltnerD.KolluriS.ShiY.QiuR.StigerT.A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.Am J Psychiatry.200816561762018413705
   PubMed Web of Science ®Google Scholar
• ZoumakisE.ChrousosGP.Corticotropin-releasing hormone receptor antagonists: an update.Endocr Dev.201017364319955754
   PubMedGoogle Scholar
• AllenNC.BagadeS.McQueenMB.loannidisJP.et al.Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.Nat Genet.20084082783418583979
   PubMed Web of Science ®Google Scholar
• HennahW.PorteousD.The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes.PLoS One.20094e490619300510
   PubMed Web of Science ®Google Scholar
• FosterA.Millerdel D.BuckleyP.Pharmacogenetics and schizophrenia.Clin Lab Med.20103097599320832661
   PubMed Web of Science ®Google Scholar
• McClayJL.AdkinsDE.AbergK.et al.Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Mol Psychiatry.201116768519721433
   PubMed Web of Science ®Google Scholar
• KirchheinerJ.SeeringerA.VivianiR.Pharmacogenetics in psychiatrya useful clinical tool or wishful thinking for the future?Curr Pharm Des.20101613614420205659
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergM.SimSC.GomezA.Rodriguez-AntonaC.Influence of cytochrome P450 polymorphisms on drug therapies: pharrnacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol Ther.200711649652618001838
   PubMed Web of Science ®Google Scholar
• KirchheinerJ.Rodriguez-AntonaC.Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.CNS Drugs.20092318119119320528
   PubMed Web of Science ®Google Scholar
• ArranzMJ.KapurS.Pharmacogenetics in psychiatry: are we ready for widespread clinical use?Schizophr Bull.2008341130114418753306
   PubMed Web of Science ®Google Scholar
• HiemkeC.Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?Eur Arch Psychiatry Clin Neurosci.2008258(Suppl 1)212718344046
   PubMed Web of Science ®Google Scholar
• FleemanN.DundarY.DicksonR.et al.Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Pharmacogenomics J.20111111420877299
   PubMed Web of Science ®Google Scholar
• OzakiN.Pharmacogenetics of antipsychoatics.Nagoya J Med Sci.2004671-21715279062
   PubMedGoogle Scholar
• FiliouMD.TurckCW.Martins-de-SouzaD.Quantitative proteomics for investigating psychiatric disorders.Proteomics Clin Appl.20115384921280236
   PubMed Web of Science ®Google Scholar
• Martins-de-SouzaD.MaccarroneG.WobrockT.et al.Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia.J Psychiatr Res.2010441176118920471030
   PubMed Web of Science ®Google Scholar
• RaedlerTJ.WiedemannK.CSF-studies in neuropsychiatrie disorders. A/euroEndocrinol Lett.200627297305
   PubMed Web of Science ®Google Scholar
• MischakH.SchanstraJP.CE-MS in biomarker discovery, validation, and clinical application.Proteomics Clin Appl.2011592321280234
   PubMed Web of Science ®Google Scholar
• RefojoD.HolsboerF.CRH signaling. Molecular specificity for drug targeting in the CNS.Ann N Y Acad Sci.2009117910611919906235
   PubMed Web of Science ®Google Scholar
• LocatelliV.BrescianiE.TamiazzoL.TorselloA.Central nervous systemacting drugs influencing hypothalamic-pituitary-adrenal axis function.Endocr Dev.20101710812019955761
   PubMedGoogle Scholar
• WiedemannK.JahnH.YassouridisA.KellnerM.Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.Arch Gen Psychiatry.20015837137711296098
   PubMed Web of Science ®Google Scholar
• DemiralayC.JahnH.KellnerM.YassouridisA.WiedemannK.Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men.Psychoneuroendocrinology.2010351438144520554120
   PubMed Web of Science ®Google Scholar
• De KloetER.JoelsM.HolsboerF.Stress and the brain: from adaption to disease.Nat Rev Neurosci.2005646347515891777
   PubMed Web of Science ®Google Scholar
• MarquesAH.SilvermanMN.SternbergEM.Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.Ann N Y Acad Sci.2009117911819906229
   PubMed Web of Science ®Google Scholar
• IsingM.HorstmannS.KloiberS.et al.Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?Biol Psychiatry.200762475417123470
   PubMed Web of Science ®Google Scholar
• SchüleC.BaghaiTC.EserD.et al.The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression.PLoS One.20094e432419177168
   PubMed Web of Science ®Google Scholar
• PaslakisG.HeuserI.SchweigerU.DeuschleM.A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine.J Psychiatr Res.2010441154115720447650
   PubMed Web of Science ®Google Scholar
• IsingM.KiinzelHE.BinderEB.NickelT.ModellS.HolsboerF.The combined dexamethasone/CRH test as a potential surrogate marker in depression.Prog Neuropsychopharmacol Biol Psychiatry.2005291085109315950349
   PubMed Web of Science ®Google Scholar
• FloresBH.KennaH.KellerJ.SolvasonHB.SchatzbergAF.Clinical and biological effects of mifepristone treatment for psychotic depression.Neuropsychopharmacology.20063162863616160710
   PubMed Web of Science ®Google Scholar
• JahnH.SchickM.KieferF.KellnerM.YassouridisA.WiedemannK.Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.Arch Gen Psychiatry.2004611235124415583115
   PubMed Web of Science ®Google Scholar
• FriessE.SchmidD.ModellS.et al.Dex/CRH-test response and sleep in depressed patients and healthy controls with and without vulnerability for affective disorders.J Psychiatr Res.2008421154116218281062
   PubMed Web of Science ®Google Scholar
• RaoU.HammenCL.PolandRE.Risk markers for depression in adolescents: sleep and HPA measures.Neuropsychopharmacology.2009341936194519262465
   PubMed Web of Science ®Google Scholar
• MurckH.NickelT.KiinzelH.et al.State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine.Neuropsychopharmacology.20032834835812589388
   PubMed Web of Science ®Google Scholar
• NuttD.LawsonC.Panic attacks: a neurochemical overview of models and mechanisms.Br J Psychiatry.19921601651781540756
   PubMed Web of Science ®Google Scholar
• KellnerM.HerzogL.YassouridisA.HolsboerF.WiedemannK.Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic.Am J Psychiatry.1995152136513677653695
   PubMed Web of Science ®Google Scholar
• GillesC.LuthringerR.Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.J Psychopharmacol.20072127228217591655
   PubMed Web of Science ®Google Scholar
• ShlikJ.AluojaA.VasarV.VasarE.PodarT.BradwejnJ.Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.J Psychiatry Neurosci.1997223323409401314
   PubMed Web of Science ®Google Scholar
• ZwanzgerP.EserD.AicherS.et al.Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenalaxis activity: a placebo-controlled study.Neuropsychopharmacology.20032897998412700707
   PubMed Web of Science ®Google Scholar
• ZwanzgerP.RupprechtR.Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.J Psychiatry Neurosci.20053016717515944741
   PubMed Web of Science ®Google Scholar
• KramerMS.CutlerNR.BallengerJC.et al.A placebo-controlled trial of L365,260, a CCKB antagonist, in panic disorder.Biol Psychiatry.1995374624667786960
   PubMed Web of Science ®Google Scholar
• van MegenHJ.WestenbergHG.den BoerJA.SlaapB.van EsRadhakishunF.PandeAC.The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.Psychopharmacology (Berl).19971292432489084062
   PubMed Web of Science ®Google Scholar
• GongQ.WuQ.ScarpazzaC.LuiS.et al.Prognostic prediction of therapeutic response in depression using high-field MR imaging.Neuroimage.2011551497150321134472
   PubMed Web of Science ®Google Scholar
• DagerSR.CorriganNM.RichardsTL.PosseS.Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.Top Magn Reson Imaging.200819819619363431
   PubMedGoogle Scholar
• PrêterM.KleinDF.Panic, suffocation false alarms, separation anxiety and endogenous opioids.Prog Neuropsychopharmacol Biol Psychiatry.20083260361217765379
   PubMed Web of Science ®Google Scholar
• EserD.LeichtG.LutzJ.et al.Functional neuroanatomy of CCK-4induced panic attacks in healthy volunteers.Hum Brain Mapp.20093051152218095276
   PubMed Web of Science ®Google Scholar
• NordM.FardeL.Antipsychotic occupancy of dopamine receptors in schizophrenia.CNS Neurosci Ther. In press.
   Google Scholar
• VyasNS.PatelNH.NijranKS.Al-NahhasA.PuriBK.The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia.Expert Rev Neurother.201111375121158554
   PubMed Web of Science ®Google Scholar